AML Detection from
Single-Cell Data
DeepOMAP processes raw single-cell RNA and protein expression from a bone marrow aspirate, identifies malignant cell populations, predicts surface protein markers, and generates a clinician-facing diagnostic report — in seconds.
Pre-loaded: de-identified bone marrow sample
Seconds, Not Weeks
Traditional flow cytometry panels take 5–14 days for full characterization. DeepOMAP delivers a comprehensive cell-type and protein landscape in under 60 seconds.
Clinically Actionable
Outputs map directly to standard AML classification (FAB/WHO) and surface proteins targeted by approved therapies — gemtuzumab, venetoclax, ivosidenib.
Beyond Bulk Sequencing
Single-cell resolution exposes heterogeneous blast populations missed by bulk RNA-seq, enabling detection of minimal residual disease and therapy-resistant subclones.
Demo Sample Profile
UnanalyzedPatient ID
AML-0137
Specimen
Bone Marrow Aspirate
Cells Captured
8,412
Assay
scRNA-seq + CITE-seq
RNA Features
33,538 genes
Protein Panel
25 ADT markers
Collection Date
De-identified
Reference Dx
AML — pending AI report